Fiche centre
Novartis Investigative Site
Zhengzhou — China
Essais liés5clinical trials
VilleZhengzhoulocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT01794780
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL | Maladie coronarienne | Phase 3 | NCT05739383 | A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | ACTIVE_NOT_RECRUITING |
| LABA based treatment: indacaterol | SEP | Phase 4 | NCT01794780 | A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator | COMPLETED |
| Ribociclib | Cancer | Phase 3 | NCT05827081 | Adjuvant WIDER — Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | RECRUITING |
| Remibrutinib (Blinded) | SEP | Phase 3 | NCT07225504 | REMASTER — A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | RECRUITING |
| Remibrutinib (Blinded) | Myasthénie | Phase 3 | NCT06744920 | RELIEVE — A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |